These novel therapies , Tirzepatide , represent a remarkable advancement in treating obesity and potentially associated conditions . These drugs are categorized as GLP-1 pathway activators , meaning they to mimic the body's GLP-1 peptide, stimulating metabolic production and lowering food intake. While Semaglutide each one operates somewhat similar